Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)
Abstract
<p>Background: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as Mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad (Incilius alvarius) and various plant species. Areas of Uncertainty: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiological role remains unclear. Safety profiles indicate low risk in controlled settings, though longer-term follow-ups with human subjects may be needed. Phenomenological overlaps with near-death experiences (NDEs) are noted but debated.Therapeutic Advances: Clinical trials have demonstrated rapid antidepressant effects. Top-line data from a recent Phase 2b trial showed that 57.5% of participants remitted from treatment-resistant depression (TRD) within eight days.1 Other Phase 2a and 2b trials have provided further, though still preliminary, evidence that 5-MeO-DMT may reduce depressive symptoms more than existing pharmacological treatments, like SSRIs.2–6Limitations: Most studies are early-phase with small samples (n ≤ 193). Only two double-blind randomized controlled trials (RCT) have been conducted in clinical populations, and long-term effects require further investigation. <h4>Conclusions:</h4> Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for TRD and other psychiatric conditions, warranting larger RCTs.</p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.